Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC) has announced the upcoming presentation of clinical results from its OTO-313 Phase 1/2 trial at the COSM conference, scheduled for April 10, 2021. Kenneth Maxwell, M.D., will present the findings, highlighting a significant step forward in addressing tinnitus, a condition currently lacking approved drug treatments. The Phase 2 trial has recently been initiated to further build on these promising results. Otonomy focuses on innovative therapeutics for neurotology, emphasizing sustained drug delivery to treat hearing loss and tinnitus.

Positive

• Successful OTO-313 Phase 1/2 trial results presented at COSM conference.
• Initiation of Phase 2 trial, indicating progress in addressing tinnitus.

Negative

• Tinnitus has no approved drug treatments currently available.

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-313 Phase 1/2 trial at the upcoming American Neurotology Society’s 56^th Annual Spring Meeting, which is part of the Combined Otolaryngology Spring Meeting (COSM), to be held virtually April 7-11, 2021. The oral presentation will be delivered on April 10, 2021 at 5:07 p.m. EDT by Kenneth Maxwell, M.D., a Neurotologist at Piedmont Ear Nose & Throat Associates in Winston-Salem, North Carolina. Dr. Maxwell was an investigator in the trial.

“We are pleased to have the opportunity to present clinical results from the OTO-313 Phase 1/2 trial to the neurotology community during the COSM conference,” said David A. Weber, Ph.D., president and CEO of Otonomy. “Tinnitus is a common condition seen by neurotologists who unfortunately have no approved drug treatments to offer patients. The Phase 2 trial we recently initiated builds on the encouraging Phase 1/2 results and is a significant step forward for this important program.”

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
cramsey@spectrumscience.com

Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

What are the results of Otonomy's OTO-313 Phase 1/2 trial?

The results demonstrated promising outcomes, leading to the initiation of a Phase 2 trial.

When will Otonomy present its clinical trial results?

Otonomy will present the results on April 10, 2021, during the COSM conference.

What is the focus of the OTO-313 clinical program?

The OTO-313 program aims to address tinnitus, a condition with no current approved drug treatments.

What is the significance of the OTO-313 Phase 2 trial?

The Phase 2 trial builds on the encouraging Phase 1/2 results, advancing the development of a potentially effective treatment for tinnitus.

Where can I find more information about Otonomy's products?

Additional information can be found on Otonomy's official website at www.otonomy.com.